| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8339073 | The Journal of Steroid Biochemistry and Molecular Biology | 2013 | 14 Pages |
Abstract
- Superior therapeutic agents to Abiraterone and Enzalutamide are required to treat CRPC.
- AKR1C3 synthesizes potent ligands for the androgen receptor locally.
- AKR1C3 is upregulated by androgen deprivation in CRPC.
- Structurally diverse, potent and selective AKR1C3 inhibitors have been developed.
- AKR1C3 inhibitors need to be tested in xenograft models and taken into preclinical development.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry
Authors
Adegoke O. Adeniji, Mo Chen, Trevor M. Penning,